MA31776B1 - Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé - Google Patents

Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Info

Publication number
MA31776B1
MA31776B1 MA32771A MA32771A MA31776B1 MA 31776 B1 MA31776 B1 MA 31776B1 MA 32771 A MA32771 A MA 32771A MA 32771 A MA32771 A MA 32771A MA 31776 B1 MA31776 B1 MA 31776B1
Authority
MA
Morocco
Prior art keywords
compound
pharmaceutical composition
glycogen phosphorylase
phosphorylase inhibiting
inhibiting compound
Prior art date
Application number
MA32771A
Other languages
Arabic (ar)
English (en)
Inventor
Pierette Banker
Eric Eugene Boros
Scott Howard Dickerson
Istvan Kaldor
Cecilia S Koble
Michael Tolar Martin
Steven Meagher Sparks
Stephen Andrew Thomson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA31776B1 publication Critical patent/MA31776B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un nouveau composé qui est un inhibiteur de la glycogène phosphorylase et son utilisation pour traiter le diabète et d'autres états associés à ce dernier. L'invention concerne également une composition pharmaceutique contenant ledit composé et des procédés pour préparer le composé et la composition pharmaceutique.
MA32771A 2007-09-28 2010-04-14 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé MA31776B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97586207P 2007-09-28 2007-09-28
PCT/US2008/077624 WO2009045830A1 (fr) 2007-09-28 2008-09-25 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Publications (1)

Publication Number Publication Date
MA31776B1 true MA31776B1 (fr) 2010-10-01

Family

ID=40098462

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32771A MA31776B1 (fr) 2007-09-28 2010-04-14 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Country Status (16)

Country Link
US (1) US20100305207A1 (fr)
EP (1) EP2195287A1 (fr)
JP (1) JP2010540552A (fr)
KR (1) KR20100087300A (fr)
CN (1) CN101932557A (fr)
AU (1) AU2008309003A1 (fr)
BR (1) BRPI0817721A2 (fr)
CA (1) CA2701120A1 (fr)
CO (1) CO6270306A2 (fr)
CR (1) CR11398A (fr)
DO (1) DOP2010000075A (fr)
EA (1) EA201000391A1 (fr)
MA (1) MA31776B1 (fr)
MX (1) MX2010003440A (fr)
WO (1) WO2009045830A1 (fr)
ZA (1) ZA201002181B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JPWO2013018735A1 (ja) 2011-07-29 2015-03-05 大正製薬株式会社 アミジン化合物又はその塩
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP7307440B2 (ja) * 2019-12-06 2023-07-12 エスケイシー・カンパニー・リミテッド 光学レンズ用ジイソシアネート組成物およびその調製方法
WO2021122645A1 (fr) 2019-12-20 2021-06-24 Syngenta Crop Protection Ag Composés azole-amide à action pesticide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025157A1 (fr) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8
CA2238298A1 (fr) * 1995-11-24 1997-06-19 Luca Francesco Raveglia Derives de quinoline
EP0906273B1 (fr) * 1996-05-24 2002-10-16 Neurosearch A/S Derives phenyle contenant un groupe acide, leur preparation et leur utilisation comme inhibiteurs des vannes a chlorure
WO2004022525A1 (fr) * 2002-09-05 2004-03-18 Neurosearch A/S Derives amide et leur utilisation en tant qu'agents bloquant les canaux chlorure
EP1565429B1 (fr) * 2002-11-21 2009-05-13 Neurosearch A/S Derives de ureido diaryle et leur utilisation medicale
JP2008519761A (ja) * 2004-11-09 2008-06-12 スミスクライン ビーチャム コーポレーション グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物

Also Published As

Publication number Publication date
BRPI0817721A2 (pt) 2015-03-31
EP2195287A1 (fr) 2010-06-16
CR11398A (es) 2010-06-28
KR20100087300A (ko) 2010-08-04
EA201000391A1 (ru) 2010-10-29
CA2701120A1 (fr) 2009-04-09
MX2010003440A (es) 2010-04-21
US20100305207A1 (en) 2010-12-02
WO2009045830A1 (fr) 2009-04-09
CN101932557A (zh) 2010-12-29
AU2008309003A1 (en) 2009-04-09
DOP2010000075A (es) 2010-07-15
JP2010540552A (ja) 2010-12-24
ZA201002181B (en) 2011-06-29
CO6270306A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
MA31776B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
MA31775B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
MA30057B1 (fr) Nucleosides antiviraux
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200800415A1 (ru) Удаление пероксида из носителя для доставки лекарственного средства
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
GEP20125506B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and use
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
MY153574A (en) Compounds and compositions as hedgehog pathway modulators
MX2009008547A (es) Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
MX2010002449A (es) Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos.
WO2008013840A3 (fr) Analogues de l'érastine et leurs utilisations
MX2012000566A (es) Combinaciones sinergicas de principios activos con feniltriazoles.
MY149070A (en) 1h-quinazoline-2,4-diones
MA28093A1 (fr) Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine
GEP20135929B (en) Compositions containing asphalt
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
IN2015DN03331A (fr)
PL1753719T3 (pl) Podstawione pirolidyn-2-ony